secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bio Green Med Solution, Inc. (BGMS)
CIK:        0001130166
Form:       8-K
Filed at:   2025-08-13T23:59:59+00:00
Accession:  0001641172-25-023296
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cyclacel faces going concern warning; cash of $3.45M expected only into Q2 2025
-------------------------------------------------------------------------------

- Auditor expresses substantial doubt about Cyclacel's ability to continue as a going concern; cash of $3.45M at March 31, 2025, expected to fund only into Q2 2025.
- Net loss of $81k for Q1 2025 vs $2.9M in Q1 2024, largely due to a $4.9M gain from deconsolidation of UK subsidiary Cyclacel Limited on Jan 24, 2025.
- Operating loss of $5.0M; R&D expenses fell to $822k from $2.8M, while G&A rose to $4.2M from $1.6M, partly due to $1.7M stock-based compensation.
- Issued Series D and E preferred stock and converted shares; common shares outstanding surged from 8.9M to 207.3M during Q1 2025.
- Regained Nasdaq compliance with equity rule on Feb 25, 2025; subject to one-year mandatory panel monitor.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1130166/000164117225023296/0001641172-25-023296-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1130166/000164117225023296/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-023296

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer